Crossmark

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Crossref DOI link: https://doi.org/10.1038/s41408-023-00821-x

Published Online: 2023-04-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shah, Mithun Vinod https://orcid.org/0000-0002-5359-336X
Tran, Elizabeth Ngoc Hoa https://orcid.org/0000-0003-1644-2287
Shah, Syed

Chhetri, Rakchha

Baranwal, Anmol https://orcid.org/0000-0002-3432-0489
Ladon, Dariusz

Shultz, Carl

Al-Kali, Aref

Brown, Anna L. https://orcid.org/0000-0002-9023-0138
Chen, Dong

Scott, Hamish S. https://orcid.org/0000-0002-5813-631X
Greipp, Patricia https://orcid.org/0000-0002-5536-9011
Thomas, Daniel

Alkhateeb, Hassan B.

Singhal, Deepak

Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Kumar, Sharad https://orcid.org/0000-0001-7126-9814
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Hahn, Christopher N. https://orcid.org/0000-0001-5105-2554
Kok, Chung Hoow https://orcid.org/0000-0002-3181-7852
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Hiwase, Devendra K. https://orcid.org/0000-0002-6666-3056
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA15083)

Mayo Clinic | Center for Clinical and Translational Science, Mayo Clinic

CSL Centenary Fellowship Medical Research Futures Fund Leukemia-Lymphoma Translational Research Program

Department of Health | National Health and Medical Research Council (GNT2007739)

Department of Health | National Health and Medical Research Council (MRF1195517)

Cancer Australia

Leukaemia Foundation
License Information

Text and Data Mining valid from 2023-04-11

Version of Record valid from 2023-04-11
More Information

Article History

Received: 19 January 2023

Revised: 15 March 2023

Accepted: 17 March 2023

First Online: 11 April 2023

Competing interests

: MVS—Research funding to the institution from AbbVie, Celgene, MRKR Therapeutics, and Astellas; AA—Research support to institution (Novartis, Astex); MP—Membership on an entity’s Board of Directors or advisory committees (Stemline Therapeutics) and Research funding (Kura Oncology); DH—Membership on an entity’s Board of Directors or advisory committees (AbbVie, Novartis). All other authors disclose no conflicts of interest.

Document is current

Any future updates will be listed below